Combination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors

Overview

RATIONALE: Drugs used in chemotherapy, such as cisplatin and doxorubicin, work in different ways to stop tumor cells from dividing so they stop growing or die. Estrogen can stimulate the growth of tumor cells. Hormone therapy using tamoxifen may fight cancer by blocking the uptake of estrogen. Combining tamoxifen with chemotherapy may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving cisplatin and doxorubicin together with tamoxifen works in treating patients with solid tumors.

Full Title of Study: “Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies”

Study Type

  • Study Type: Interventional
  • Study Design
    • Primary Purpose: Treatment
    • Masking: None (Open Label)

Detailed Description

OBJECTIVES: – Determine the feasibility and efficacy of cisplatin, doxorubicin, and tamoxifen (CAT) in patients with soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer. – Determine the toxicity of this regimen in these patients. OUTLINE: Patients receive cisplatin IV over 1-2 hours followed immediately by doxorubicin IV over 15-30 minutes on days 1-3 and oral tamoxifen twice daily on days 4-17. Treatment continues every 3 weeks in the absence of the total cumulative doxorubicin dose reaching at least 500 mg/m2, disease progression, or unacceptable toxicity. Patients who achieve partial remission (PR) undergo local surgery or radiotherapy, if feasible, to convert PR to complete remission. Patients are followed every 2 months for 1 year and then every 3 months for 2 years. PROJECTED ACCRUAL: A total of 14-30 patients will be accrued for this study.

Interventions

  • Drug: cisplatin
  • Drug: doxorubicin hydrochloride
  • Drug: tamoxifen citrate
  • Procedure: conventional surgery
  • Radiation: radiation therapy

Participating in This Clinical Trial

DISEASE CHARACTERISTICS:

  • Histologically proven soft tissue sarcoma, glioma, mesothelioma, hepatoma, thyroid cancer, or adrenal cancer with clinical, radiological, or histologic evidence of incurability – Patients with thyroid cancer must have failed radioactive iodine – Measurable or evaluable disease PATIENT CHARACTERISTICS: Age: – 65 and under Performance status: – ECOG 0-2 Hematopoietic: – Granulocyte count at least 1,500/mm3 – Platelet count at least 140,000/mm3 Hepatic: – Bilirubin normal Renal: – Creatinine less than 1.47 mg/dL Cardiovascular: – Left ventricular ejection fraction at least 50% by MUGA scan – No congestive heart failure – No severe, uncontrolled hypertension – No ischemia, life-threatening arrhythmia, or conduction disturbance by ECG Other: – No allergy to study medications – No uncontrolled infection – No active abuse of ethanol that would preclude treatment – No other prior or concurrent malignancy – Not pregnant – Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: – Not specified Chemotherapy: – No more than 1 prior chemotherapy regimen – No prior anthracycline or cisplatin – At least 3 weeks since other prior chemotherapy and recovered Endocrine therapy: – Not specified Radiotherapy: – See Disease Characteristics – No prior radiotherapy to more than 25% of bone marrow – At least 3 weeks since other prior radiotherapy and recovered Surgery: – Not specified

Gender Eligibility: All

Minimum Age: N/A

Maximum Age: 65 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Ottawa Regional Cancer Centre
  • Overall Official(s)
    • Stan Z. Gertler, MD, FRCPC, Study Chair, Ottawa Regional Cancer Centre

Citations Reporting on Results

Gertler SZ, Yau J, Stewart DJ, et al.: Cisplatin, doxorubicin and tamoxifen (CAT) in the treatment of incurable soft tissue and endocrine malignancies-preliminary results. [Abstract] Proceedings of the American Society of Clinical Oncology 15: A1427, 1996.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.